Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $13.46 million versus the consensus estimate of $13.56 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.